203 related articles for article (PubMed ID: 8780547)
1. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
Ellerhorst JA; Sella A; Amato RJ; Tu SM; Millikan RE; Finn LD; Banks M; Logothetis CJ
Cancer; 1997 Dec; 80(11):2128-32. PubMed ID: 9392335
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
7. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
[TBL] [Abstract][Full Text] [Related]
8. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
10. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
12. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
13. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
Marx G; Taylor J; Goldstein D
Intern Med J; 2005 Jan; 35(1):34-8. PubMed ID: 15667466
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
[TBL] [Abstract][Full Text] [Related]
16. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Atzpodien J; Kirchner H; Illiger HJ; Metzner B; Ukena D; Schott H; Funke PJ; Gramatzki M; Jürgenson S; Wandert T; Patzelt T; Reitz M
Br J Cancer; 2001 Oct; 85(8):1130-6. PubMed ID: 11710825
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
18. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
